Rigel Pharmaceuticals Q1 2024 GAAP EPS $(0.05) Misses $(0.03) Estimate, Sales $29.534M Miss $31.284M Estimate
Rigel Pharmaceuticals Q1 2024 GAAP EPS $(0.05) Misses $(0.03) Estimate, Sales $29.534M Miss $31.284M Estimate
锐杰制药2024年第一季度GAAP每股收益美元（0.05）未达到预期（0.03），销售额为2953.4万美元，低于3128.4万美元的预期
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $29.534 million which missed the analyst consensus estimate of $31.284 million by 5.59 percent. This is a 13.29 percent increase over sales of $26.070 million the same period last year.
锐杰制药（纳斯达克股票代码：RIGL）公布的季度亏损为每股0.05美元，比分析师普遍预期的0.03美元（0.03美元）低66.67％。这比去年同期每股亏损0.08美元（0.08）增长了37.5％。该公司公布的季度销售额为2953.4万美元，比分析师普遍预期的3128.4万美元低5.59％。这比去年同期的260.7亿美元销售额增长了13.29％。